www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

US EUROPE AFRICA ASIA 中文
Business / Companies

GE bullish on biopharmaceutical market

By Zhu Wenqian in Wuhan (China Daily) Updated: 2016-05-17 10:40

GE bullish on biopharmaceutical market

A technician at YZYBio, a biopharmaceutical company based in Wuhan, capital of Hubei province. China's market for biological medicine and devices is expected to grow significantly.GUAN XIN/CHINA DAILY

General Electric Healthcare Co, a leader in the high-end medical devices market, said it is bullish on the long-term growth of the biopharmaceutical market in China, and the market for biological medicine and devices is expected to grow significantly.

Last year, China reported about 4.3 million new cancer cases, and that number accounts for 20 percent of global new cancer cases. The rising cancer rates have posed a major health problem for the country, according to a report by the American Cancer Society.

GE Healthcare recently unveiled its first modular biopharmaceutical factory, which consists of 62 modules, in a biotech zone in Wuhan, Hubei province. China became the first country to receive GE's cutting-edge factory that was prefabricated in Germany, where it took 18 months to complete construction. The multinational healthcare provider also plans to put more top R&D effort into China.

"Local manufacturing in China is a more affordable way to provide modern therapies for deadly diseases like cancer, a leading cause of death in China," said Jan Makela, general manager of BioProcessing Life Sciences at GE Healthcare.

"Biological medical products are considered as a critical way to fight against major diseases such as cancer and diabetes," he added.

"Putting the factory into operation will accelerate the development of biopharmaceutical industry in China, and assist pharmaceutical manufacturers in speeding up manufacturing and launching of biological medicines."

JHL Biotech, a biological products manufacturer in Taiwan that is backed by Silicon Valley venture capitalists, bought the factory. The company will manufacture biological medicines and monoclonal antibodies for late-stage clinical trials and commercial supply.

"We hope to work with GE to build JHL into a world-class biopharmaceutical factory, accelerate capacity improvement in Asia and meet potential market demand. In addition, we will be able to manufacture the one-time largest number of cells in Asia after the facility was put into operation," said Racho Jordanov, CEO and co-founder of JHL Biotech.

The global biological medicine market is currently estimated to be worth $200 billion, taking up 20 percent of the overall medicine market, and the biological medicine sector sees a growth rate of around 10 percent to 12 percent annually.

China is still in the early stages of developing biopharmaceutical manufacturing. In China, where biological medicine currently takes only 4 percent of the domestic medicine market, the growth rate is seen as being exponential in coming years. By 2019, the biological medicine market in China is expected to reach $350 million, surging from $44 million in 2009, according to a study of the Global Biosimilars Market that was published in 2014.

Last year, China announced the national initiative "Made in China 2025", which was designed to transform the nation from a manufacturing giant of quantity into a world power of manufacturing quality.

zhuwenqian@chinadaily.com.cn

Hot Topics

Editor's Picks
...
主站蜘蛛池模板: 亚洲成人精品久久 | 精品久久久久久中文字幕网 | www.欧美xxxx| 欧美一区在线观看视频 | 男人桶女人暴爽的视频 | 国产夫妻视频 | 国产精品自在欧美一区 | 久久久久无码国产精品一区 | 亚洲成人影院在线观看 | 精品国产1区 | 国产午夜人做人视频羞羞 | 99国产精品欧美久久久久久影院 | 午夜影院黄色片 | 男人扒开腿躁女人j | 激情一区二区三区成人 | 国产一级特黄一级毛片 | 精品伊人久久久久网站 | 亚洲免费网站观看视频 | 一本久道综合久久精品 | 九九在线观看精品视频6 | 国产亚洲福利一区二区免费看 | 久青草国产在线 | 一级女性全黄生活片免费 | 国产高清视频免费观看 | 国产精品三级a三级三级午夜 | 国产永久在线视频 | 韩国免费a级毛片 | 欧美成在线 | 丝袜足液精子免费视频 | 亚洲日本欧美产综合在线 | 9久9久热精品视频在线观看 | 亚洲精品一区二区在线观看 | 夜间福利在线观看 | 99在线精品免费视频九九视 | 老司机午夜精品网站在线观看 | 最新国产一区二区精品久久 | 日本久久久久一级毛片 | 九九九免费视频 | 男女午夜免费视频 | 久久综久久美利坚合众国 | 亚洲日本韩国在线 |